Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
J Struct Biol. 2024 Sep;216(3):108113. doi: 10.1016/j.jsb.2024.108113. Epub 2024 Jul 28.
Kainate receptors play an important role in the central nervous system by mediating postsynaptic excitatory neurotransmission and modulating the release of the inhibitory neurotransmitter GABA through a presynaptic mechanism. To date, only three structures of the ligand-binding domain (LBD) of the kainate receptor subunit GluK1 in complex with positive allosteric modulators have been determined by X-ray crystallography, all belonging to class II modulators. Here, we report a high-resolution structure of GluK1-LBD in complex with kainate and BPAM538, which belongs to the full-spanning class III. One BPAM538 molecule binds at the GluK1 dimer interface, thereby occupying two allosteric binding sites simultaneously. BPAM538 stabilizes the active receptor conformation with only minor conformational changes being introduced to the receptor. Using a calcium-sensitive fluorescence-based assay, a 5-fold potentiation of the kainate response (100 μM) was observed in presence of 100 μM BPAM538 at GluK1(Q), whereas no potentiation was observed at GluK2(VCQ). Using electrophysiology recordings of outside-out patches excised from HEK293 cells, BPAM538 increased the peak response of GluK1(Q) co-expressed with NETO2 to rapid application of 10 mM L-glutamate with 130 ± 20 %, and decreased desensitization determined as the steady-state/peak response ratio from 23 ± 2 % to 90 ± 4 %. Based on dose-response relationship experiments on GluK1(Q) the EC of BPAM538 was estimated to be 58 ± 29 μM.
kainate 受体通过介导突触后兴奋性神经递质传递,并通过突触前机制调节抑制性神经递质 GABA 的释放,在中枢神经系统中发挥重要作用。迄今为止,通过 X 射线晶体学已经确定了配体结合域 (LBD) 与正变构调节剂结合的 kainate 受体亚基 GluK1 的仅三个结构,它们都属于 II 类调节剂。在这里,我们报告了 GluK1-LBD 与 kainate 和 BPAM538 复合物的高分辨率结构,BPAM538 属于全跨度 III 类。一个 BPAM538 分子结合在 GluK1 二聚体界面上,从而同时占据两个变构结合位点。BPAM538 稳定活性受体构象,仅对受体引入微小的构象变化。使用钙敏感荧光基础测定法,在 100 μM BPAM538 存在下,观察到 100 μM kainate 反应(100 μM)的 5 倍增强(100 μM),而在 GluK2(VCQ) 中未观察到增强。使用从 HEK293 细胞分离的外侧片的电生理学记录,BPAM538 增加了与 NETO2 共表达的 GluK1(Q)的峰反应对 10 mM L-谷氨酸的快速应用,并且将去敏化确定为稳态/峰反应比从 23 ± 2%降低到 90 ± 4%。基于 GluK1(Q)的剂量反应关系实验,BPAM538 的 EC 估计为 58 ± 29 μM。